A Phase 3 interventional study of Naproxen sodium ER (BAYH6689) and Advil in Pain, sponsored by Bayer. Completed at 10 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-15.
Sponsored by Bayer · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 7th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 3, and was the 6th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 253 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
14 studies in Pain by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Pain by Bayer, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 4th registered.
Bayer’s Pain studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pilot trial to demonstrate that consumers can appropriately select Aleve 24 Hour for their own use based on expected duration of pain greater than 12 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
Drug: Naproxen sodium ER (BAYH6689) · Drug: Advil
Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
Commercially available Advil; oral caplet upon incidence of pain
The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours
Participants were instructed to select a product for use upon their pain episode and then call a toll-free number for an interview within 30 minutes of the selection decision. Participants who did not call were interviewed after 14 days for data collection. The primary endpoint was derived from 2 variables: 1) number of participants who selected Naproxen Sodium ER and reported expected duration of pain less than or equal to 12 hrs (A); 2) number of participants who selected Naproxen Sodium ER and report expected duration of pain greater than 12 hrs (B). The results was calculated as B/(A+B).
Time frame: up to 14 days
The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours
Time frame: Within 24 hours of their selection decision taken up to 14 days
The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours
In addition to the primary outcome measure evaluated for all selection evaluable participants, this secondary outcome was evaluated separately for low literacy participants. Low Literacy Participants are defined as those who had REALM (Rapid Estimate of Adult Literacy in Medicine) score \</= 60 at visit 1.
Time frame: Up to 14 days
| Milestone | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| Started | 253 |
| Treated | 237 |
| Completed | 235 |
| Not completed | 18 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Incomplete information for analysis | 2 |
| Withdrew: Did not take any product | 6 |
Participants were instructed to select a product for use upon their pain episode and then call a toll-free number for an interview within 30 minutes of the selection decision. Participants who did not call were interviewed after 14 days for data collection. The primary endpoint was derived from 2 variables: 1) number of participants who selected Naproxen Sodium ER and reported expected duration of pain less than or equal to 12 hrs (A); 2) number of participants who selected Naproxen Sodium ER and report expected duration of pain greater than 12 hrs (B). The results was calculated as B/(A+B).
| Percentage of participants | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours | 72.0 (64.9 to 78.4) |
| Percentage of participants | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| The Percentage of Participants Who Selected Naproxen Sodium ER , Expected Their Pain to Last More Than 12 Hours and Reported Their Selection Decision Within First 24 Hours | 71.5 (63.6 to 78.6) |
In addition to the primary outcome measure evaluated for all selection evaluable participants, this secondary outcome was evaluated separately for low literacy participants. Low Literacy Participants are defined as those who had REALM (Rapid Estimate of Adult Literacy in Medicine) score \</= 60 at visit 1.
| Percentage of participants | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| The Percentage of Low Literacy Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours | 64.5 (45.4 to 80.8) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium ER (BAY H6689) or Advil IR | — | 0/237 (0%) | 14/237 (5.9%) |
| Event | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| Back painMusculoskeletal and connective tissue disorders | 2/237 |
| NephrolithiasisRenal and urinary disorders | 1/237 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/237 |
| ToothacheGastrointestinal disorders | 1/237 |
| HeadacheNervous system disorders | 1/237 |
| Pain in extremityGeneral disorders | 1/237 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/237 |
| SomnolenceNervous system disorders | 1/237 |
| ContusionInjury, poisoning and procedural complications | 1/237 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/237 |
| Age, Continuous(Years) | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| Mean | 51.4 ± 14.3 |
| Gender(Participants) | Naproxen Sodium ER (BAY H6689) or Advil IR |
|---|---|
| Female | 119 |
| Male | 115 |
The record gives a start of Jul 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Ibuprofen